Truemed and ThrivePass Partner to Expand Access to Healthcare Through HSA/FSA Dollars 
Axio BioPharma Expands Advisory Board with Leaders in Biologics Development and Manufacturing
Seasoned Executives Join to Support AI-Driven Growth in U.S.-Based Biomanufacturing MADISON, Wis., June 16, 2025 /PRNewswire/ -- Axio BioPharma Inc., a...
Quest Analytics Announces Strategic Integration Partnership with Arcadia
On showcase at AHIP 2025: The integrated solution delivers advanced provider performance intelligence within Quest Analytics' flagship network management technology...
Pager Health (SM) Launches Industry’s First End-to-End Member Navigation Platform
Pager Health Navigator redefines the member experience by connecting provider, clinical, benefits, and program navigation in one seamless, AI-powered solution...
OSSIO Launches Small OSSIOfiber® Suture Anchors, Expanding Best-in-Class Portfolio of Bio-Integrative, Metal-Free Implants to Improve Soft Tissue Fixation
‘The future of orthopedics’WOBURN, Mass.--(BUSINESS WIRE)--#biointegrative--OSSIO Inc., a fast-growing medical technology company focused on evolving orthopedic surgery with bio-integrative, metal-free...
Bennett Blau Joins Evercore as Senior Managing Director in the Healthcare Investment Banking Group
NEW YORK--(BUSINESS WIRE)--Evercore (NYSE: EVR) announced today that Bennett Blau has joined the firm as a senior managing director in...
Home Run! Adia Med of Winter Park’s AHCA Triumph Brings Insurance-Covered Healing to Patients
Winter Park, Florida--(Newsfile Corp. - June 16, 2025) - Adia Nutrition, Inc. (OTCQB: ADIA), a leading innovator in regenerative medicine...
Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy
First Patients Expected to be Enrolled This MonthHalifax, Nova Scotia--(Newsfile Corp. - June 16, 2025) - Sona Nanotech Inc. (CSE:...
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced...
RayStation used for pioneering clinical milestone at Helsinki University Hospital – first treatment with accelerator-based BNCT in Europe
STOCKHOLM, June 16, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that RayStation®*, its advanced treatment planning...
Leader Healthcare Implements SAP S/4HANA Public Cloud With Accely To Drive Operational Excellence
With SAP S/4HANA Public Cloud, the foremost healthcare equipment supplier in the UAE starts a digital transformation journey to improve...
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for...
D-Bal Max 2025: Exploring the Science and Safety behind a Popular And Legal Dianabol Steroid For Muscle Growth
D-bal-max D-Bal MAX Glasgow, June 15, 2025 (GLOBE NEWSWIRE) -- In the quest for enhanced athletic performance and muscle growth,...
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with...
Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of...
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients with Duchenne has been re-assessed,...
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52Data...
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in...
IDC Report: Huawei Ranks No.1 in Global Wrist-Worn Market in Q1
Huawei wearable devices Surpassed 200 Million Cumulative Shipments SHENZHEN, China, June 14, 2025 /PRNewswire/ -- According to the latest IDC Worldwide Quarterly...
Decisely Notifies Individuals of Data Security Incident
ALPHARETTA, Ga., June 13, 2025 /PRNewswire/ -- Decisely learned of a data security incident that may have involved personal and/or protected...
Abstractive Health Launches Clinical Time Machine, the First AI Game Built on Real Historical Patient Records
NEW YORK--(BUSINESS WIRE)--#digitalhealth--Abstractive Health has launched Clinical Time Machine, an AI-driven simulation that immerses physicians in diagnostic cases using real...